WEST PHARMACEUTICAL SERVICES, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $3.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2026-06-30 was $3.50M.
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-06-30 was $0.00.
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $4.50M, a 1400.00% increase from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $300.00K, a 93.02% decline from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $4.30M, a 22.86% increase from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $3.50M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|
| 2026-06-30 | $3.50M 10-Q · filed 2026-07-23 | $3.50M 10-Q · filed 2026-07-23 | |
| 2025-12-31 | $4.50M 10-K · filed 2026-02-17 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-23 | $0.00 10-Q · filed 2026-07-23 | |
| 2024-12-31 | $300.00K 10-K · filed 2026-02-17 | ||
| 2023-12-31 | $4.30M 10-K · filed 2026-02-17 | ||
| 2022-12-31 | $3.50M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |